Degludec Glargine U300 Hospital Study

NCT05036876 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

220

Enrollment

OTHER

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: Degludec
DRUG: Glargine U300

Sponsor

Medanta, The Medicity, India